


(moved from page 18 of the Specification as filed)

CLAIMS

What is claimed is:

1. Use of the hydrogenated pyrido [4,3-b] indole derivatives of the formula (I)



wherein R_1 is Me, Et or PhCH_2 ;

R_2 is H, PhCH_2 or 6-Me-3-Py- $(\text{CH}_2)_2$;

R_3 is H, Me or Br;

provided that

(a) when $---$ represents a single bond, then

$R_1 = R_3 = \text{Me}$; $R_2 = \text{H}$; and the compound is in the form of a cis (\pm) isomer; or

(b) when $---$ represents a double bond, then

(i) $R_1 = \text{Et}$ or PhCH_2 , $R_2 = R_3 = \text{H}$,

(ii) $R_1 = R_3 = \text{Me}$, $R_2 = \text{PhCH}_2$,

(iii) $R_1 = \text{Me}$, $R_2 = 6\text{-Me-3-Py-}(\text{CH}_2)_2$, $R_3 = \text{H}$,

(iv) $R_1 = R_3 = \text{Me}$, $R_2 = 6\text{-Me-3-Py-}(\text{CH}_2)_2$,

(v) $R_1 = \text{Me}$, $R_2 = \text{H}$, $R_3 = \text{H}$ or Me,

(vi) $R_1 = \text{Me}$, $R_2 = \text{H}$, $R_3 = \text{Br}$,

and salts thereof with pharmacologically acceptable acids and quaternary derivatives as the agents for the treatment of neurodegenerative diseases.